Gilead's Trodelvy for breast cancer endorsed by EMA panel
Sundry Photography/iStock Editorial via Getty Images

The Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion on Gilead Sciences' (NASDAQ:GILD) Trodelvy (sacituzumab govitecan) for HR+/HER- pretreated breast cancer.
A final decision from the EMA is expected later this year.

If the indication is approved, it would be for patients who have received endocrine-based therapy and at least two additional systemic therapies
The recommendation is supported by phase 3 data showing Trodelvy led to a statistically significant overall survival benefit of 3.2 months compared to single-agent chemotherapy.

More on Gilead Sciences

Gilead: Pharma Play Worth Watching On Multitude Of ASCO Data Readouts
Gilead Sciences Now Barely A Hold, Market Looks Uninspired (Rating Downgrade)
Gilead Sciences: Patience